https://www.businesswire.com/news/home/20190716005999/en/

GERMANTOWN, Md.--(BUSINESS WIRE)--Jul 16, 2019--

Senseonics Holdings, Inc. (“Senseonics” or “Company”) (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced preliminary financial results for the second quarter of 2019.